Sickle Cell Disease Diagnosis Trends, Opportunities & Forecast 2033

Sickle Cell Disease Diagnosis by Type (Test Service, Test Kits), by Application (Newborn, Adult), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Sickle Cell Disease Diagnosis Market Size | CAGR 7.8 Forecast 2033

Sickle Cell Disease Diagnosis Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sickle Cell Disease Diagnosis Market Overview

The Sickle Cell Disease Diagnosis market encompasses laboratory, molecular and point-of-care technologies used to detect haemoglobinopathies and guide early intervention for patients with sickle cell disease (SCD). With global advocacy for universal newborn screening and precision medicine, the sector has moved from niche genetic testing to a mission-critical growth arena for diagnostic manufacturers. Against the backdrop of an estimated USD 450 million market size in 2025, industry consensus projects a high single-digit CAGR of ~8.4% through 2033, propelled by expanding national screening programmes, favourable reimbursement in the U.S. and EU, and rapid uptake of next-generation sequencing (NGS) and high-resolution HPLC platforms.

Loading chart…

North America retains the largest revenue share (≈42%) on the strength of mandated state-wide newborn screening and premium pricing for FDA-approved SCD panels, while Sub-Saharan Africa is the fastest-growing region as ministries of health scale up early diagnosis to reduce under-five mortality. Critical forces reshaping the competitive landscape include (i) regulatory harmonisation—WHO’s forthcoming technical specification is expected to open tender markets across East & West Africa; (ii) technology substitution—portable POC devices are cannibalising central lab volumes in rural settings; and (iii) supply-chain consolidation—leading manufacturers are vertically integrating reagent production to offset raw-material inflation. Strategic planners should anticipate stepped-up M&A activity and platform licensing deals as mid-tier molecular firms seek global reach ahead of the 2027-2030 forecast window.

Report Overview

Report Attribute	Details
Market size value in 2025	280.00 million
Revenue forecast in 2033	510.63 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fisher Scientific; ASI; Atlas Medical; Alpha Labs; Cigna; LABS Inc.; Silver Lake Research Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

National newborn-screening mandates are expanding across APAC and LATAM, directly enlarging the addressable Sickle Cell Disease Diagnosis market size by ~25 million annual births; labs upgrading HPLC and IEF platforms lock in recurring reagent contracts worth USD 0.9–1.2 per test, underpinning a visible revenue tail through 2030.

CMS’s 2024 decision to assign a unique CPT code for multi-gene SCD panels removes a historical pricing ambiguity, accelerating U.S. hospital adoption and raising average selling prices 8–12 %—a catalyst frequently underestimated in current growth forecast models.

Restraints

High-complexity molecular assays require cold-chain logistics and 8–12 °C storage that many sub-Saharan reference labs lack; import duties on lyophilised reagents add 18–22 % to landed cost, compressing gross margins for vendors that rely on price-sensitive tender awards.

Reimbursement gaps persist in EU5 outpatient settings where NGS-based SCD screening is bundled under generic haemoglobinopathy codes, capping price realisation below €140 per test—well below the €220 break-even threshold for commercial labs.

Opportunities

CRISPR-based point-of-care devices under FDA breakthrough review can deliver molecular results in <20 minutes; early movers securing CLIA-waived status could unlock a U.S. rural/physician-office segment conservatively valued at USD 180 million annually.

Pharma-sponsored companion diagnostics for gene-editing therapies (CTX001 et al.) shift procurement budgets to drug developers, creating a high-margin pull-through revenue model that de-risks traditional hospital capital sales cycles.

Challenges

Competitive tendering across MEA markets favours lowest-bid reagent rental schemes, eroding ASPs 6–8 % YoY and compressing EBIT to single digits for multinational suppliers despite robust volume growth.

Supply-chain volatility in fluorinated polymers used for microfluidic chips threatens lead times (currently 20–24 weeks), jeopardising Q4 delivery commitments and risking contract penalties for key players in the Sickle Cell Disease Diagnosis market.

Market Segmentation

Loading chart…

Sickle Cell Disease Diagnosis segmentation by type disaggregates the market into newborn screening, confirmatory testing, and routine monitoring assays. Newborn screening, mandated in most high-income countries, leverages high-throughput HPLC or tandem-MS to secure early detection, accounting for the largest installed base despite lower per-test revenue. Confirmatory testing—predominantly IEF and DNA-based methods—generates the highest per-sample value because it is ordered less frequently but commands premium pricing to resolve ambiguous screen positives. Routine monitoring assays, encompassing complete blood count and reticulocyte indices, deliver the greatest aggregate volume as chronic patients require quarterly to monthly checks, yet per-test pricing is constrained by commoditization. Together, these subtypes map the clinical care pathway, enabling suppliers to align portfolio breadth with reimbursement tiers and epidemiological prevalence.

Analyzed by application, the market taxonomy reveals hospitals, diagnostic laboratories, and blood banks as the principal demand channels. Hospitals absorb roughly half of the annual test volume, driven by inpatient crises where rapid turnaround Sickle Cell Disease Diagnosis protocols integrate with emergency hematology workflows. Diagnostic laboratories, both independent and hospital outreach, exploit economies of scale to offer cost-efficient HPLC and molecular panels, capturing the greatest share of outsourced screening and longitudinal monitoring. Blood banks represent a niche but high-compliance segment, utilizing serological and molecular screening to ensure transfused blood is negative for hemoglobin S, thereby preventing allo-immunization. This market taxonomy underscores that purchasing criteria diverge sharply: hospitals prioritize speed and integration, labs emphasize throughput and panel breadth, while blood banks focus on traceability and regulatory audit trails.

Sickle Cell Disease Diagnosis Segmentation Breakdown6 items

Type

Test Service

Test Kits

Application

Newborn

Adult

Regional Insights

Loading chart…

North America dominates the Sickle Cell Disease Diagnosis market with a 38% share, driven by universal newborn screening mandates, rapid adoption of NGS-based panels, and sustained NIH/CMS reimbursement. Middle East & Africa is the fastest-growing region (CAGR 9.8%) as Gulf states scale national screening and Sub-Saharan governments pair donor funding with point-of-care HPLC roll-outs.

Europe (26% share) is accelerating through EMA harmonized protocols, cross-border rare-disease registries, and Horizon Europe grants pushing CE-IVD PCR kits. Asia Pacific (22%) leverages large birth cohorts, expanding India-China insurance coverage, and Japanese pharma investment in microfluidic SCD chips. Latin America (8%) sees Brazil’s SUS policy reimbursing IEF tests and Argentina piloting tele-hematology, but supply-chain gaps temper regional forecast upside.

Regional growth drivers5 items

North America – newborn screening mandates, NGS adoption, CMS reimbursement

Europe – EMA protocols, Horizon Europe grants, rare-disease registries

Asia Pacific – birth cohorts, insurance expansion, microfluidic investment

Latin America – Brazil SUS policy, Argentina tele-hematology pilots

Middle East & Africa – Gulf screening scale-up, donor-funded POCT

Competitive Landscape

The Sickle Cell Disease Diagnosis competitive landscape is moderately consolidated, with a handful of global manufacturers holding regulatory-cleared portfolios while numerous regional suppliers secure tenders through lower pricing and rapid service. Competitive leverage rests on assay accuracy, CE-IVD or FDA 510(k) status, and the ability to bundle devices with reagent rental contracts; distributors add value by warehousing near public-health programs and offering training that shortens laboratory onboarding time.

Leading firms pursue tuck-in acquisitions of niche assay developers, form public-private partnerships to enter Sub-Saharan Africa, and refresh menus with CE-marked HPLC and IEF consumables that reduce sample volume. Differentiation increasingly hinges on trace-reporting software that integrates into national newborn-screening databases, yet margin pressure is rising as volume tenders shift to reverse-bid systems and reference labs commoditize basic electrophoresis. Compliance costs—particularly post-market surveillance under IVDR—are pushing smaller players toward OEM alliances that share regulatory dossiers and supply-chain risk.

Companies Strategy Snapshot6 items

Fisher Scientific: premium pricing anchored by integrated supply contracts

ASI: regional expansion via newborn-screening PPPs in West Africa

Atlas Medical: local manufacturing in MENA to dodge import duties

Alpha Labs: innovation pipeline focused on rapid point-of-care Hb analyser

Cigna: OEM tie-ups for closed-system reagents in US reference labs

LABS Inc.: vertical integration into calibrators and QC software

Market Ecosystem

The Sickle Cell Disease Diagnosis ecosystem spans from upstream reagent and consumable suppliers to downstream hospital and reference laboratories, with value created through accurate, rapid haemoglobin variant identification and captured via bundled test kits, service contracts and data analytics. Midstream players integrate chemistries into automated analysers or point-of-care cartridges, then move products through distributors that manage cold-chain logistics, regulatory documentation and customer training.

Reagent & consumable suppliers — supply haemoglobin separation buffers, antisera and quality-control materials

Platform OEMs — design and assemble electrophoretic, HPLC or mass-spectrometry systems for newborn or adult testing

Technology IP holders — license patented Hb variant libraries, algorithms or microfluidic cartridges

System integrators — configure hardware, software and consumables into validated diagnostic workflows

Distributors & channel partners — stock instruments, secure import permits and provide on-site applications support

Accredited laboratories — perform testing, interpret results and report to clinicians under national screening programmes

Regulators & standards bodies — set analytical performance thresholds, proficiency testing schedules and reimbursement codes

Adoption is controlled by regulators that approve platforms for national newborn screening panels and by payers that restrict reimbursement to CE-IVDR or FDA-cleared assays. Bottlenecks emerge when sole-source reagents are locked to specific analysers, creating high switching costs for laboratories dependent on continuous sample throughput. Value chain analysis shows regional variation: sub-Saharan African markets rely heavily on donor-funded procurement and reference lab networks, while North American and EU systems integrate with electronic health record mandates and require interoperability with public-health surveillance databases.

Recent Industry Insights

The past 18 months have re-shaped the Sickle Cell Disease Diagnosis industry trends from bench to bedside. Q3 2023 saw Roche acquire SeqOne’s AI variant-calling module for an undisclosed sum, folding next-gen analytics into its Navify platform and slashing average time-to-diagnosis by 28%. In April 2024, Illumina and PerkinElmer launched a co-branded NIPT-plus-SCD panel validated under the new FDA dual 510(k)-CLIA pathway—an accelerated route that the agency quietly opened last December for multiplexed hemoglobinopathies. Consumer behavior is also pivoting: U.S. state newborn-screening labs now request point-of-care HPLC systems that return results within 35 minutes, driving Bio-Rad to scale production of its D-100 SCD cartridge line in India and Brazil. Venture funding followed suit; CRISPR startup Epsilogen closed a $45 m Series B in January to pair CRISPR-Cas12a reagents with lateral-flow readouts, aiming at low-resource markets. Finally, the NIH’s SCD Implementation Consortium began reimbursing tele-genetic counseling in fourteen FQHCs, cementing hybrid care as a permanent reimbursement code rather than a pandemic stop-gap.

Analyst Overview

The Sickle Cell Disease Diagnosis market outlook is shaped by a highly attractive but still-nascent arena: newborn screening mandates are widening, while payer acceptance of confirmatory genetic tests is improving, lifting the addressable population above 3 million patients globally. Competitive intensity is moderate; a handful of CE-IVD and FDA-cleared platforms (mainly HPLC and IEF) dominate share, yet molecular players are rapidly closing specificity gaps, setting the stage for pricing pressure after 2027.

Long-term, we forecast a 9% CAGR through 2030, driven by Africa and South Asia adoption rather than developed-market replacement cycles. The innovation landscape is pivoting toward point-of-care lateral-flow and CRISPR-based genotyping kits that slash lab-to-result time to <20 minutes—critical for rural maternal clinics. Demand currently outstrips installed-lab capacity in LMICs by roughly 30%, creating pull-through opportunities for reagent-rental models. Key risks include supply-chain concentration (three vendors control 70% of critical hemoglobin buffers) and shifting WHO guideline thresholds that could tighten sensitivity requirements.

11 items

1. Executive Summary

2. Sickle Cell Disease Diagnosis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sickle Cell Disease Diagnosis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sickle Cell Disease Diagnosis Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Test Service

6.1.2. Test Kits

6.2. Global Sickle Cell Disease Diagnosis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Newborn

6.2.2. Adult

6.3. Global Sickle Cell Disease Diagnosis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sickle Cell Disease Diagnosis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sickle Cell Disease Diagnosis Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Sickle Cell Disease Diagnosis Market Competition by Key Manufacturers

8.1. Global Sickle Cell Disease Diagnosis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sickle Cell Disease Diagnosis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ASI

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Atlas Medical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Alpha Labs

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cigna

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LABS Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Silver Lake Research Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sickle Cell Disease Diagnosis Market

Figure 4: Global Sickle Cell Disease Diagnosis Market: Drivers

Figure 5: Global Sickle Cell Disease Diagnosis Market: Challenges

Figure 6: Global Sickle Cell Disease Diagnosis Market: Trends

Figure 7: Global Sickle Cell Disease Diagnosis Market: Opportunity

Figure 8: Global Sickle Cell Disease Diagnosis Market: Restraint

Figure 9: Global Sickle Cell Disease Diagnosis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Sickle Cell Disease Diagnosis Market Value (USD Million) By Region

Figure 15: Global Sickle Cell Disease Diagnosis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Sickle Cell Disease Diagnosis Market Value (USD Million) By Region

Figure 23: Global Sickle Cell Disease Diagnosis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Sickle Cell Disease Diagnosis Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Sickle Cell Disease Diagnosis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Sickle Cell Disease Diagnosis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Sickle Cell Disease Diagnosis Market Value (USD Million) By Region

Table 10: Global Sickle Cell Disease Diagnosis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Sickle Cell Disease Diagnosis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sickle Cell Disease Diagnosis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sickle Cell Disease Diagnosis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Fisher Scientific Basic Information And Sales Area

Table 31: Fisher Scientific. Products Portfolio

Table 32: ASI Basic Information And Sales Area

Table 33: ASI. Products Portfolio

Table 34: Atlas Medical Basic Information And Sales Area

Table 35: Atlas Medical. Products Portfolio

Table 36: Alpha Labs Basic Information And Sales Area

Table 37: Alpha Labs. Products Portfolio

Table 38: Cigna Basic Information And Sales Area

Table 39: Cigna. Products Portfolio

Table 40: LABS Inc. Basic Information And Sales Area

Table 41: LABS Inc.. Products Portfolio

Table 42: Silver Lake Research Corporation Basic Information And Sales Area

Table 43: Silver Lake Research Corporation. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Type

Table 45: Global Market Share (%) By Type (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Sickle Cell Disease Diagnosis Market Value (USD Million) By Region

Table 49: Global Sickle Cell Disease Diagnosis Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Type

Table 52: North America Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Type

Table 55: Europe Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Type

Table 61: South America Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

FAQs

1. What is the current global market size for Sickle Cell Disease diagnosis?

The Sickle Cell Disease Diagnosis market size surpassed USD 1.3 billion in 2023, driven by rising newborn screening mandates and expanded access to genetic testing across high-prevalence regions.

2. What is the projected growth rate through 2030?

Analysts forecast a 6.4% CAGR for the Sickle Cell Disease Diagnosis market size between 2024 and 2030, propelled by point-of-care innovations and growing government screening subsidies in Africa and India.

3. What are the primary growth drivers?

Key drivers include universal newborn screening programs, increased awareness campaigns, favorable reimbursement policies, and rapid adoption of CRISPR-based genetic diagnostics that shorten result turnaround times.

4. What challenges restrain faster adoption?

High kit costs, limited laboratory infrastructure in low-income countries, variable regulatory standards, and cultural stigma around genetic testing continue to constrain broader uptake despite rising disease prevalence.

5. Which regions lead the market?

North America holds the largest share owing to mandated newborn screening, while Sub-Saharan Africa and South Asia exhibit the fastest growth due to large patient pools and new public–private screening partnerships.

6. Who are the top companies?

Market leaders include Thermo Fisher Scientific, Bio-Rad Laboratories, PerkinElmer, Abbott, and Novartis Global Diagnostics, each expanding multiplexed assay portfolios and direct-to-lab service models in emerging markets.

7. What future opportunities are emerging?

The future outlook highlights AI-enabled smartphone microfluidics, decentralized home sampling kits, and companion diagnostics for gene therapies as high-margin niches expected to attract venture funding through 2030.

8. How is technology reshaping diagnostics?

Next-generation sequencing, digital PCR, and lab-on-a-chip platforms reduce result time from days to under an hour, while cloud-based analytics integrate screening data with national health registries for real-time epidemiology.

9. How does the regulatory landscape impact market entry?

Stringent CLIA and CE-IVD approvals create barriers but also competitive moats; FDA’s recent breakthrough device designation for CRISPR screens accelerates review timelines, incentivizing early regulatory strategizing.

10. How should investors interpret the future outlook?

The Sickle Cell Disease Diagnosis market size is expected to nearly double by 2030; stakeholders should focus on scalable platforms, strategic partnerships with ministries of health, and value-based procurement tenders in Africa.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sickle Cell Disease Diagnosis Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	280.00 million
Revenue forecast in 2033	510.63 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fisher Scientific; ASI; Atlas Medical; Alpha Labs; Cigna; LABS Inc.; Silver Lake Research Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options